AptaPrecision: Personalized screening for minimal residual disease in multiple myeloma
Unmet Medical Need: Minimal residual disease (MRD) is the major cause for relapse of blood cancers such as multiple myeloma (MM), acute and chronic lymphoid leukemias, and acute myeloid leukemia. However, current methods for MRD detection in MM depend on invasive, failure-prone bone marrow aspiration procedures, and therefore do not offer sufficient timeliness and reliability.
Envisioned Healthcare Product: The AptaPrecision team has created a method for noninvasive detection of tumor load, thus allowing timely and reliable MRD detection in order to improve screening results and treatment outcomes, while also reducing screening costs.
Stage of Development: Hypothesis testing, proof of concept
Columbia-Coulter Funding Cycle: 2016-2017